Answers are grounded in this paper and cite their sources.
Background Liver-transplant (LT) recipients requiring prolonged ventilation and considered for percutaneous dilatational tracheostomy (PDT) have high short-term mortality, but LT-specific tools to support prognosis-aligned communication at this decision point are lacking. We developed and internally validated a simple PDT-day model and an integer Tracheostomy Decision-Point Risk Score (TRS) to estimate 90-day mortality from the PDT decision point in LT recipients undergoing PDT. Methods This retrospective single-center cohort included 83 adult LT recipients undergoing PDT between December 2010 and June 2024. The primary outcome was all-cause mortality within 90 days from the PDT decision point, operationalized as the day of PDT. The model estimates risk after the PDT decision point and not the causal effect of PDT. Logistic regression used routinely available PDT-day variables; internal validation used bootstrap shrinkage. Discrimination and calibration were assessed by AUC, Brier score, calibration-in-the-large, and calibration slope. Coefficients were converted to an integer TRS. Results 90-day mortality was 62.7% (52/83). Model for End-Stage Liver Disease (MELD; +5 points), age (+ 10 years), and activated partial thromboplastin time (aPTT; +5 s) measured on the PDT day were independently associated with 90-day mortality (adjusted odds ratios 2.54 [95% confidence interval (CI) 1.45–4.47], 1.97 [1.16–3.36], and 1.53 [1.02–2.28], respectively; all p ≤ 0.040). Discrimination was good (AUC 0.846; bootstrap-corrected AUC 0.829 [95% CI 0.74–0.93]) with favorable calibration (calibration-in-the-large − 0.01; slope 1.02). The TRS (+ 2 points per + 5 MELD, + 2 per + 10 years, + 1 per + 5 s aPTT) retained discrimination (AUC 0.831) and stratified observed 90-day mortality: 38% (14/37) low, 72% (13/18) intermediate, and 89% (25/28) high. 90-day survival differed across bands (global log-rank p < 0.001). Conclusions For LT recipients who reach the PDT decision point and undergo PDT, the TRS provides internally validated 90-day mortality estimates that may support prognosis-informed multidisciplinary deliberation and bedside risk communication. It should be used only as one component of decision-making and does not estimate the causal effects of PDT, no-PDT strategies, or PDT timing. Use in prolonged-ICU LT recipients without PDT requires separate validation.
No takes yet. Share an insight, caveat, or question.
Jalč et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: